JP2020533382A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533382A5
JP2020533382A5 JP2020515147A JP2020515147A JP2020533382A5 JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5 JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020515147 A JP2020515147 A JP 2020515147A JP 2020533382 A5 JP2020533382 A5 JP 2020533382A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
sequence identity
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020515147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/056967 external-priority patent/WO2019053611A1/en
Publication of JP2020533382A publication Critical patent/JP2020533382A/ja
Publication of JP2020533382A5 publication Critical patent/JP2020533382A5/ja
Priority to JP2023120187A priority Critical patent/JP2023139178A/ja
Priority to JP2025093685A priority patent/JP2025131722A/ja
Pending legal-status Critical Current

Links

JP2020515147A 2017-09-14 2018-09-12 癌の組合せ治療 Pending JP2020533382A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023120187A JP2023139178A (ja) 2017-09-14 2023-07-24 癌の組合せ治療
JP2025093685A JP2025131722A (ja) 2017-09-14 2025-06-04 癌の組合せ治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762558575P 2017-09-14 2017-09-14
US62/558,575 2017-09-14
PCT/IB2018/056967 WO2019053611A1 (en) 2017-09-14 2018-09-12 POLY THERAPY FOR THE TREATMENT OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023120187A Division JP2023139178A (ja) 2017-09-14 2023-07-24 癌の組合せ治療

Publications (2)

Publication Number Publication Date
JP2020533382A JP2020533382A (ja) 2020-11-19
JP2020533382A5 true JP2020533382A5 (enExample) 2021-10-21

Family

ID=63713944

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515147A Pending JP2020533382A (ja) 2017-09-14 2018-09-12 癌の組合せ治療
JP2023120187A Pending JP2023139178A (ja) 2017-09-14 2023-07-24 癌の組合せ治療
JP2025093685A Pending JP2025131722A (ja) 2017-09-14 2025-06-04 癌の組合せ治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023120187A Pending JP2023139178A (ja) 2017-09-14 2023-07-24 癌の組合せ治療
JP2025093685A Pending JP2025131722A (ja) 2017-09-14 2025-06-04 癌の組合せ治療

Country Status (7)

Country Link
US (3) US11401334B2 (enExample)
EP (1) EP3694878A1 (enExample)
JP (3) JP2020533382A (enExample)
CN (1) CN111108125A (enExample)
BR (1) BR112020005079A2 (enExample)
CA (1) CA3075714A1 (enExample)
WO (1) WO2019053611A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
PH12021552986A1 (en) * 2019-05-31 2023-08-14 Dana Farber Cancer Inst Inc Combination therapy
EP4085076A4 (en) 2020-01-03 2024-01-24 Biosion, Inc. BCMA-BINDING ANTIBODIES AND USES THEREOF
CA3210069A1 (en) * 2021-03-03 2022-09-09 Tong Zhu Antibody-drug conjugates comprising an anti-bcma antibody
CN118591560A (zh) * 2022-01-25 2024-09-03 葛兰素史密斯克莱知识产权发展有限公司 癌症的组合疗法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2562411A1 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ES2408216T3 (es) 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
US7687456B2 (en) 2005-11-09 2010-03-30 Proteolix, Inc. Compounds for enzyme inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
BR122014008753A2 (pt) 2008-06-17 2015-12-29 Millennium Pharm Inc compostos de éster boronato e composições farmacêuticas dos mesmos
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
PH12013502421A1 (en) 2011-05-27 2014-01-06 Glaxo Group Ltd Bcma (cd269/tnfrsf17) -binding proteins
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
UY35091A (es) 2012-10-24 2014-05-30 Onyx Therapeutics Inc Formulaciones de liberacion modificada para oprozomib
EP2914628A1 (en) 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
PL2953972T3 (pl) 2013-02-05 2021-03-08 Engmab Sàrl Metoda wyboru przeciwciał przeciwko bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
JP6285274B2 (ja) 2014-04-28 2018-02-28 株式会社ブリヂストン バイアスタイヤ及びその製造方法
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN106573042A (zh) * 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
SG10201900931XA (en) 2014-12-05 2019-02-27 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
DK3226897T3 (da) 2014-12-05 2021-04-19 Memorial Sloan Kettering Cancer Center Antistoffer der rammer b-cellemodningsantigen og fremgangsmåder til anvendelse
ES3012402T3 (en) * 2015-04-13 2025-04-09 Pfizer Therapeutic antibodies and their uses
PT3331910T (pt) 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
EP3147954A1 (en) 2015-09-22 2017-03-29 Nokia Technologies Oy Photodetector with conductive channel made from two dimensional material and its manufacturing method
EP4015537A1 (en) * 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof

Similar Documents

Publication Publication Date Title
JP2020533382A5 (enExample)
JP2020500538A5 (enExample)
JP2017528476A5 (enExample)
MX2025004236A (es) Anticuerpo anti proteina reguladora de se?ales alfa (sirpalfana)
JP2020508303A5 (enExample)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2018507220A5 (enExample)
JP2024167313A5 (enExample)
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
NZ603972A (en) Anti-fgfr2 antibodies
FI3740504T3 (fi) CD70-yhdistelmähoito
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2020533383A5 (enExample)
JP2017534577A5 (enExample)
JP2018535650A5 (enExample)
JP2019504032A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2018035138A5 (enExample)
RU2021103288A (ru) МОЛЕКУЛЫ СО СПЕЦИФИЧНОСТЬЮ В ОТНОШЕНИИ CD79 и CD22
JP2017535257A5 (enExample)
JP2011528902A5 (enExample)
JP2013542194A5 (enExample)
ME02807B (me) HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE
JP2010516229A5 (enExample)
NZ623347A (en) Novel anti-dr5 antibody